(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of 15.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Novo Nordisk A S's revenue in 2023 is $22,115,740,740.On average, 3 Wall Street analysts forecast NVO's revenue for 2023 to be $64,412,326,545,600, with the lowest NVO revenue forecast at $63,039,838,400,000, and the highest NVO revenue forecast at $66,074,408,048,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2024 to be $70,676,447,424,000, with the lowest NVO revenue forecast at $68,946,820,976,000, and the highest NVO revenue forecast at $72,472,836,304,000.
In 2025, NVO is forecast to generate $77,727,799,600,000 in revenue, with the lowest revenue forecast at $76,169,150,112,000 and the highest revenue forecast at $79,286,449,088,000.